Look out, AZ. Lilly and Boehringer's Jardiance is ready to roll in chronic kidney disease after FDA nod
Fierce Pharma
SEPTEMBER 22, 2023
Fast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., | After AstraZeneca's Farxiga won a class-first chronic kidney disease approval back in 2021, Eli Lilly and Boehringer are entering the fray with (..)
Let's personalize your content